NanoFCM
NanoFCM is a privately held instrumentation company that builds nano-flow cytometry platforms (Flow NanoAnalyzer, Single-Molecule NanoAnalyzer) plus reagents and sample-analysis services for single-particle characterization of biological nanoparticles (7–1000 nm), serving biopharmaceutical developers, vaccine/gene therapy researchers, and academic labs across 30+ countries.
- Company typePrivate
- Founded2018
- HeadquartersNottingham, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NanoFCM does
NanoFCM is a privately held scientific-instrument company that designs and manufactures nano-flow cytometry platforms for single-particle analysis of biological nanoparticles in the 7–1000 nm range. The company's product stack centers on two instruments—the Flow NanoAnalyzer, which combines light-scattering sizing/concentration measurement with multi-channel fluorescence detection, and the Single-Molecule NanoAnalyzer, which extends detection to individual fluorophores, proteins, and mRNAs for cargo-loading quantification on LNPs and extracellular vesicles. A supporting reagents and consumables line (calibration standards, fluorescent quantification reagents, fluorescent antibodies) generates recurring revenue, while a sample-analysis services offering provides contract characterization for customers who prefer outsourced workups. The firm is incorporated as NanoFCM Co., Ltd. in Xiamen, China, and operates an EMEA Operations Center in Stevenage, UK, a Singapore APAC office, plus a North America sales and applications function, reaching customers in at least 30 countries through both direct sales and a network of regional distributors.
The company sells primarily to biopharmaceutical and vaccine/gene therapy developers—including 80% of the Top 20 biopharma, per company-cited scale metrics—who require single-particle characterization of LNPs, extracellular vesicles, viral vectors, and other nanomedicines for drug development and quality control. Secondary segments include academic and clinical research laboratories and clinical/food-safety applications. Pricing is not publicly disclosed and follows a quote-based, demo-led enterprise sales motion supplemented by technical webinars, peer-reviewed publication references (1,000+ cumulative citations), and platinum-level sponsorship of the ISEV annual meeting for seven consecutive years (2018–2026). Distribution is structured around direct enterprise sales plus exclusive arrangements such as DKSH for selected Asian markets and a growing approved service-provider network (RoosterBio in the US).
Operationally, NanoFCM reported 11–50 employees, no disclosed funding rounds or parent entity, and no published revenue. The 2024 launch of an industrial flagship (Flow NanoAnalyzer Flare) and a high-throughput nano-flow system (Auto20) marks the firm's most material product move and indicates a strategic shift from research-grade sale toward regulated bioprocess QC use cases.
NanoFCM firmographics
Firmographics- Name
- NanoFCM
- Legal name
- NanoFCM Co., Ltd.
- Website
- https://nanofcm.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NanoFCM is a privately held instrumentation company that builds nano-flow cytometry platforms (Flow NanoAnalyzer, Single-Molecule NanoAnalyzer) plus reagents and sample-analysis services for single-particle characterization of biological nanoparticles (7–1000 nm), serving biopharmaceutical developers, vaccine/gene therapy researchers, and academic labs across 30+ countries.
- Ownership category
- akta.pro rank
NanoFCM industry classification
Industry- Product category
- Analytical Instrumentation
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
- SIC
- Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
- akta.pro secondary industries
- Flow Cytometry & Cellular Analysis Diagnostics (HLAHAAAF), Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK)
Keywords
Where NanoFCM is headquartered
LocationHeadquarters
- HQ city
- Nottingham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices4 records
Markets served
NanoFCM business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Flow NanoAnalyzer Instruments: Sale of analytical instruments (Flow NanoAnalyzer, Single-Molecule NanoAnalyzer) for nanoparticle characterization. Instruments enable multiparameter analysis of biological nanoparticles at single-particle level for research and quality control applications.
- Reagents and Consumables: Sale of supporting reagents including quality control materials, size standards, fluorescent quantification reagents, and fluorescent antibodies for use with NanoAnalyzer platforms.
- Sample Analysis Services: Contract analytical services using NanoAnalyzer platform, offered through service provider partnerships like RoosterBio. Sample analysis services for extracellular vesicle characterization.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
NanoFCM product offering
Product offeringCore offering
NanoFCM designs, manufactures, and sells nano-flow cytometry instruments (Flow NanoAnalyzer and Single-Molecule NanoAnalyzer) for multiparameter analysis of individual biological nanoparticles in the 7-1000 nm range. The company combines light scattering for size/concentration measurement with fluorescence detection for biochemical characterization, and also supplies supporting reagents, consumables, and contract sample analysis services for biopharma and academic customers.
Product overview
NanoFCM provides a unified platform of nanoparticle characterization instruments centered on the Flow NanoAnalyzer and Single-Molecule NanoAnalyzer, both designed for multiparameter analysis of biological nanoparticles (7-1000 nm) at the single-particle level. The Flow NanoAnalyzer combines light scattering and fluorescence detection for simultaneous size, concentration, and biochemical property measurement, while the Single-Molecule NanoAnalyzer extends this capability to detect individual fluorophores, proteins, and mRNAs for detailed molecular characterization. Supporting these instruments are reagent and consumable products plus sample analysis services, enabling comprehensive nanoparticle characterization across applications including extracellular vesicles, nanomedicines, vaccines, viruses, and bacteria.
Differentiator
Problem solved
Functional benefit
Brands
- Flow NanoAnalyzer: Main product platform for multiparameter analysis of functional nanoparticles (7-1000 nm) at single-particle level, combining light scattering for size measurement and fluorescence detection for biochemical characterization
- Single-Molecule NanoAnalyzer
Products and services
- Flow NanoAnalyzer High-sensitivity flow cytometry system for multiparameter characterization of nanoparticles (7-1000 nm) at the single-particle level, combining light scattering for size/concentration measurement with fluorescence detection for biochemical property analysis; sold to biopharma and research institutions.
- Single-Molecule NanoAnalyzer Advanced single-molecule detection platform for analyzing individual fluorophores, proteins, and mRNAs, enabling characterization of extracellular vesicles, mRNA LNPs, and viral vectors at the single-molecule level for nanobiological drug loading applications.
- Reagents and Consumables Quality control reagents, size standards, fluorescent quantification reagents, and fluorescent antibodies designed for use with Flow NanoAnalyzer systems.
- Sample Analysis Services Contract analytical services for nanoparticle characterization using the NanoAnalyzer platform, including exosome/EV analysis, LNP characterization, and custom nanoparticle analysis, offered directly and through approved service providers such as RoosterBio.
Quantifiable outcome
- Size resolution comparable to TEM with fast acquisition times of 1-2 minutes
- +3 more outcomes
Companies that use NanoFCM
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
NanoFCM technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
NanoFCM partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered major and minor.
- RoosterBiomajorStrategic partnership making RoosterBio the first US-based approved service provider for exosome/EV analytical services using NanoFCM's NanoAnalyzer. RoosterBio offers contract analytical services integrating NanoAnalyzer technology within exosome process development programs and provides expert knowledge for protocol development.
- DKSH TechnologymajorExclusive partnership for marketing, sales, distribution and after-sales service support in selected Asian markets including Singapore, Taiwan, and Thailand. DKSH provides local market access and distribution infrastructure for NanoFCM's analytical instruments.
- Cyto-LogicminorRegional distribution partner for Poland. Contact: [email protected]
- ANAMET s.r.o.minorRegional distribution partner for Czech Republic. Contact: [email protected]
- Cold Spring Biotech CORP.minorRegional distribution partner for Taiwan, China. Contact: +886 2 2695 9990
- Meiwafosis Co., Ltd.minorRegional distribution partner for Japan. Contact: [email protected]
- NewSpec Pty LtdminorRegional distribution partner for Australia. Contact: [email protected]
Scale indicators4 records
Recent moves5 records
Expansion highlights6 records
NanoFCM competitors and assessment
Company assessmentEmerging players
- Bio-Techne: Supplies exosome/EV reagents, antibodies, and isolation kits (ExoDx, ExoQuick). Overlaps with NanoFCM's reagent/consumables business and shares the same EV-research customer base, creating both partnership and competitive dynamics.
- Nanoview Biosciences: Single-EV analysis platform (ExoView) using microarray-based immunocapture plus interferometric imaging. Direct competitor in the EV characterization market, frequently co-cited with NanoFCM in EV research publications.
- RoosterBio: MSC and EV bioprocess supplier and NanoFCM's first US approved service provider for exosome/EV analytical services. Although a partner, RoosterBio also develops its own EV analytics offerings and competes for the same biopharma EV development budget.
- Cytek Biosciences: Spectral flow cytometry innovator (Aurora, Northern Lights) bringing advanced flow-based cell analysis to immunology, cell therapy, and oncology. Overlaps with NanoFCM in serving cell-therapy and EV analytical workflows using flow-based single-particle measurement.
- Spectradyne: Maker of nCS1 Microfluidic Resistive Pulse Sensing instruments for nanoparticle sizing and concentration. Competes with NanoFCM directly in LNP, EV, and viral vector characterization, particularly in biopharma QC.
Direct peers
- Particle Metrix: Maker of ZetaView NTA systems that compete head-to-head with NanoFCM in EV/exosome quantification and characterization. Both target academic core facilities and biopharma process development with comparable single-particle workflows.
- Malvern Panalytical (NanoSight): Maker of NanoSight Nanoparticle Tracking Analysis instruments, which is the most widely used competing technique for sub-micron particle sizing. Both NanoFCM and NanoSight target EV, LNP, and exosome characterization workflows in biopharma and academia.
- Izon Science: Developer of qNano / TRPS tunable resistive pulse sensing instruments for single-particle nanoparticle sizing and concentration. Izon is the closest alternative technique to NanoFCM's single-particle analysis, serving overlapping EV, virus, and LNP characterization markets.
Broad incumbents
- Beckman Coulter Life Sciences: Dominant flow cytometry incumbent (CytoFLEX, Navios, DxFLEX) with broad biopharma and clinical diagnostics reach. NanoFCM directly extends flow cytometry into the sub-500 nm range Beckman does not cover, making Beckman the most strategically relevant incumbent — and the most likely large competitor.
- BD Biosciences: Global flow cytometry leader (BD FACSDiscover, BD Symphony) with the largest installed base in pharma and academia. BD has the resources to enter the nano-flow space and already supplies the broader cell-analysis workflow in which NanoFCM's EV/virus customers operate.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
NanoFCM social profiles
Digital presenceNanoFCM financial estimates
Financial estimateRevenue estimate
Valuation estimate
NanoFCM leadership team
Management profileNumber of profiles
Profiles2 records
NanoFCM funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NanoFCM M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NanoFCM
What does NanoFCM do?
NanoFCM designs, manufactures, and sells nano-flow cytometry instruments (Flow NanoAnalyzer and Single-Molecule NanoAnalyzer) for multiparameter analysis of individual biological nanoparticles in the 7-1000 nm range. The company combines light scattering for size/concentration measurement with fluorescence detection for biochemical characterization, and also supplies supporting reagents, consumables, and contract sample analysis services for biopharma and academic customers.
Is NanoFCM a public or private company?
NanoFCM is a private company. It is classified as unknown and is currently operating.
When was NanoFCM founded?
NanoFCM was founded in 2018. It employs 11 to 50 people.
Where is NanoFCM based?
NanoFCM is headquartered in Nottingham, United Kingdom, in the Europe region.
How does NanoFCM make money?
Three revenue lines are on record. Flow NanoAnalyzer Instruments are the primary driver. The others are reagents and Consumables and sample Analysis Services.
Who are NanoFCM's main competitors?
Emerging players on record are Bio-Techne, Nanoview Biosciences, RoosterBio, Cytek Biosciences and Spectradyne. Direct peers are Particle Metrix, Malvern Panalytical (NanoSight) and Izon Science. Broad incumbents are Beckman Coulter Life Sciences and BD Biosciences.
Does NanoFCM have an API?
No public API is recorded for NanoFCM.
What industry is NanoFCM in?
NanoFCM's product category is Analytical Instrumentation. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HLAHAAAF, Flow Cytometry & Cellular Analysis Diagnostics. Its NAICS code is 334516 and its SIC code is 3826.